Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aarli JA, Behan WMH, Behan PO (eds) (1987) Clinical neuroimmunology. Blackwell, Oxford
Abel JJ, Rowntree LG, Turner BB (1914) Plasma removal with return of corpuscles. J Pharm Exp Ther 5: 625–641
Adler H (1937) Thymus und Myasthenie. Arch Klin Chir 189: 529–532
Agishi T (1983) Technical aspects of double filtration plasmapheresis. Plasma Ther Transfus Technol 4: 397–404
Agishi T, Kaneko I, Hasuo Y et al. (1980) Double filtration plasmapheresis. Trans Am Soc Artif Intern Org 26: 406–411
Akizawa T, Koshikawa S (1987) Activated complement and leukotrien profiles during membrane plasmapheresis: indices of blood membrane interaction. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 44–50
Aufeuvre JP, Morin F, Cohen-Solal M, Lefloch A, Baudelot J (1980)Hazards of plasma exchange. In: Sieberth HG (ed) Plasma exchange. Schattauer, Stuttgart, S 149–157
Austin JH (1965) Recurrent polyneuropathies and their cortico-steroid treatment. Brain 81: 157–192
Barandun S, Morell A (1981) Adverse reactions to immunoglobulin preparations. In: Nydegger UE (ed) Immunohemotherapy. A guide to immunoglobulin prophylaxis and therapy. Academic Press, London, p 223
Behan PO, Behan WMH (1987) Plasma exchange in neurological diseases. Brit Med J 295: 283–284
Behm E, Falkenhagen D, Zinner G, Courtney JM, Klinkmann H (1987) Interactions of IM-P and IM-T adsorbents with complement components. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 493–498
Benedik M, Drinovec J, Varl J, Ponikvar R, Koselj M (1988) The influence of chronic plasma exchange on serum aluminium levels in a patient with normal renal function. In: Rock G (ed) Apheresis. Alan R. Liss, New York
Berger GMB, Miller JL, Bonnici F, HA Joffe, DW Dubovsky (1978) Continuous flow plasma exchange in the treatment of homozygous familial hypercholesterolemia.Am J Med 65: 243–251
Berning T, Krummenerl T, Glaser J, Paulus H, van Husen N (1988) Immunadsorption - eine neue Therapie der Myasthenia gravis. Med Klin 83: 125–128
Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A (1983) Myasthenia gravis: Long term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33: 1316–1321
Besinger UA, Fateh-Moghadam A, Knorr-Held S, Wick M, Kissel H, Albiez M (1987) Immunomodulation in myasthenia gravis by high-dose intravenous 7-S immunoglobulins. Ann NY Acad Sei 505: 828–831
Biggs R (ed) (1976)Human Blood Coagulation, Hemostasis and Thrombosis. Blackwell, Oxford
Blalock A (1944) Thymectomy in the treatment of myasthenia gravis. J Thorac Surg 13: 316–339
Borberg H (1981) Problems of plasma exchange therapy. In: Gurland HJ, Heinze V, Lee HA (eds) Therapeutic plasma exchange. Springer, Berlin Heidelberg New York, S 191–201
Borberg H, Stoffel W, Oette K (1983) The development of specific plasma immunoabsorption.Plasma Ther Transfus Technol 4: 459–466
Burgstaler E, Pineda AA (1981) Immunoabsorption in an extracorporeal plasma perfusion system: in vitro studies.Artif Organs 5: 259
Behan PO, Behan WMH (1987) Plasma exchange in neurological diseases. Brit Med J 295: 283–284
Bystryn JC, Graf MW, Uhr JW (1970) Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med 132: 1279–1287
Castino F, Scheucher K, Malchesky PS, Koshino I, Nose Y (1976) Microemboli-free blood detoxification utilizing plasma filtration. Trans Am Soc Artif Intern Organs 22: 637–645
Charlton B, Schindhelm K, Smeby LC, Farrell PC (1985) Analysis of immunoglobulin G kinetics in the non-steady state J Lab Clin Med 105: 312–320
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Co Tui, Bartter FC, Wright AM, Holt RB (1944) Red cell reinfusion and the frequency of plasma donations. JAMA 124: 331–336
Consensus Development Conference, National Institutes of Health. (1986) The utility of therapeutic plasmapheresis for neurological disorders. JAMA 256: 1333–1337
Cook SK, Dowling PC, Murray MR, Whitaker JN (1971) Circulating demyelinating factors in acute idiopathic polyneuropathy. Arch Neurol 24: 136–144
Craddock PR, Hammerschmidt DE, White JG, Dalmasso AP, Jacob HS (1977) Complement (C5a)-induced granulocyte aggregation in vitro: A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 60: 260–264
Dagher FJ, Lyons JH, Finlayson DC, Shamsai J, Moore FD (1965) Blood volume measurement: A critical study.Adv Surg 1: 69–109
Dalakas MC, Engel WK (1981) Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment.Ann Neurol (Suppl) 9: 134–145
Dau PC (1980) Plasmapheresis therapy in myasthenia gravis.Muscle Nerve 3: 468–482
Dau PC (1984) Plasmapheresis: Therapeutic or experimental procedure? Arch Neurol 41: 647–653
Delwaide PJ, Salmon J, von Cauwenberger H (1967) Premiers essais de traitement de la myasthenie par azathioprine. Acta Neurol Belg 67: 701–712
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50: 621–637
Dyck PJ, Lais AC, Hansen SM, Sparks MF, Low PA, Parathasarathy S, Baumann WJ (1982) Technique assessment of demyelination from endoneurial injection. Exp Neurol 77: 359–377
Dyck PJ, O’Brien PC, Oviatt KF et al. (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11: 136–141
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461–465
Edelman GM, Marchalonis JJ (1967) Preparation of antigens and antibodies. In: Williams CA, Chase MW (eds) Methods in Immunology and Immunochemistry, Vol I.Academic Press, New York
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Engel AG, Sahashi K, Lambert EH, Howard FM (1979) The ultrastructural localization of the acetylcholine receptor, immunoglobulin G and the third and ninth complement component at the motor end-plate and their implications for the pathogenesis of myasthenia gravis. In: Aguayo AJ, Karpati G (eds) Current topics in nerve and muscle research. Excerpta Medica, Amsterdam, pp 111–122
Euler HH, Krey U, Schroeder O, Lofiler H (1985) Membrane plasmapheresis technique in rats. Confirmation of antibody rebound. J Immunol Methods 84: 313–319
Euler HH, Schroeder JO, Löffler H (1987) The antibody rebound phenomenon as a rationale for synchronizing plasmapheresis with pulse cytotoxic drugs. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 200–207
Fabre M, Andreu G, Mannoni P (1980) Some biological modifications and clinical hazards observed during plasma exchanges. In: Sieberth HG (ed) Plasma Exchange. Schattauer, Stuttgart, pp 143–148
Forsgren A, Sjöquist J (1966) Protein A from Staphylococcus aureus. I. Pseudo-immune reaction with human gammaglobulin. J Immunol 97: 822–827
Frank MM, Hamburger MI, Lawley TJ, Kimberley RP, Plötz PH (1979) Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 300: 518–523
French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome (1987) Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 22: 753–761
Ghebrehiwet B, Müller-Eberhard HJ (1979) C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. J Immunol 123: 616–621
Gibbels E, Toyka KV, Borberg H, Haupt WF, Hann P (1986) Plasmaaustauschbehandlung bei chronischen Polyneuritiden vom Typ Guillain-Barre. Nervenarzt 57: 129–139
Goudswaard J, Virella G, Noordzij A, Pol J (1977) Isolation of equine IgG ( T) by hydrophobic interaction chromatography. Immunochemistry 14: 717–719
Graw RG, Herzig GP, Eisel RS, Perry S (1971) Leucocyte and platelet collection from normal donors with the continuous flow blood cell separator. Transfusion 11: 94–101
Grob D (ed) (1981) Myasthenia gravis: Pathophysiology and management. Ann NY Acad Sei 377
Gross MLP, Thomas PK (1981) The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sei 52: 69–78
Grossman L (1985) Are sham procedures needed in clinical trials of plasmapheresis? Plasma Ther Transfus Technol 6: 780–786
Güsken G, Kotitschke R, Gaczkowski A, Kadar J, Borberg H (1987) Serum preserve as a replacement fluid for plasma exchange therapy. Plasma Ther Transfus Technol 8: 333–341
Guillain-Barré Syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barré syndrome Neurology 35: 1096–1104
Handley SL (1981) Therapeutic apheresis: industry research report. Unterberg & Towbin, New York
Härtung H-P, Hadding U. (1983) Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol 6: 283–326
Härtung H-P, Schwenke C, Bitter-Suermann D, Toyka KV (1987) Guillain-Barré syndrome: Activated complement components C3a and C5a in CSF. Neurology 37: 1006–1009
Härtung H-P, Heininger K, Schäfer B, Fierz W, Toyka KV (1988) Immune mechanisms in inflammatory polyneuropathy. Ann NY Acad Sei 540: 122–161
Heininger K, Liebert UG, Toyka KV et al. (1984) Chronic inflammatory polyneuropathy: Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulins. J Neurol Sei 66: 1–14
Heininger K, Hendricks M, Toyka KV (1985) Myasthenia gravis: A new semiselective procedure to remove acetyl-choline receptor autoantibodies from plasma. Plasma Ther Transfus Technol 6: 771–775
Heininger K (1986) Stellenwert der Bestimmung der Acetylcholin-Rezeptorantikörper in der Diagnostik und Verlaufsbeurteilung der Myasthenia gravis. Dissertation, München
Heininger K, Toyka KV, Gaczkowski A, Härtung H-P, Borberg H, Grabensee B (1986) Selective removal of pathogenic factors in neurologic diseases. Plasma Ther Transfus Technol 7: 351–357
Heininger K, Härtung H-P, Toyka KV, Gaczkowski A, Borberg H (1987) Therapeutic plasma exchange in myasthenia gravis: Semiselective adsorption of anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels. Ann NY Acad Sei 505: 898–900
Heininger K, Toyka KV, Borberg H (1987) Selective removal of antibodies: Theoretical and practical aspects. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic Plasmapheresis, Vol VI. ISAO Press, Cleveland, pp 136–142
Heininger K, Toyka KV (1988) Current status of plasma exchange in neurology. Plasma Ther Transfus Technol 9: 69–72
Heininger K, Toyka KV, Gibbels E, Besinger UA, Borberg H, Härtung H-P, Grabensee B (1990) Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyneuropathy. Prog Clin Biol Res 337: 275–281
Hellstrom KE, Hellstrom I (1981) Does perfusion with treated plasma cure cancer? N Engl J Med 305: 1215–1216
Hugli TE, Chenoweth DE (1980) Biologically active peptides of complement: techniques and significance of C3a and C5a measurement. In: Nakamura RM (ed) Future Perspectives in Clinical Laboratory Immunoassays. Alan R. Liss, New York
Iizuka I, Yamazaki Z, Kanai F (1984) A study of direct hemoperfusion using a new immunocomplex adsorbent IMP. In: Oda T (ed), Therapeutic Plasmapheresis, Vol III. Schattauer, Stuttgart, pp 277–282
Ilyas AA, Willison HJ, Quarles RH et al. (1988) Serum antibodies to gangliosides in Guillain-Barrd syndrome. Ann Neurol 23: 440–447
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Kanazawa H, Nagasato K, Shirabe M, Kihara M, Shibuya N (1985) Changes of lymphocyte subsets during plasmapheresis. In: Oda T (ed) Therapeutic Plasmapheresis, Vol IV. Schattauer, Stuttgart, pp 561–565
Khatri, BO, McQuillen MP, Harrington GJ, Sachmoll D, Hoffmann RG (1985) Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 35: 312–319
Klein J (1982) Immunology. The science of self-nonself discrimination. Wiley, New York
Koski CL, Humphry R, Shin ML (1985) Anti-peripheral myelin antibody in patients with demyelinating polyneuropathy: Quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 82: 905–909
Koski CL, Chou D, Jungalwala FB (1987) Myelin lipids bound by serum antibodies to peripheral myelin (a-PNM Ab) in patients with Guillain-Barre syndrome. Neurology 37: 253 (abstract)
Kronvall G, Williams RC (1969) Differences in anti-protein A activity among IgG subgroups. J Immunol 103: 828–833
Leibowitz S, Hughes RAC (1983) Immunology of the nervous system. Arnold, London
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Limburg PC, The H, Hummel-Tappel E, Oosterhuis HJGH (1983) Anti acetylcholine receptor antibodies in myasthenia gravis. I. Their relation to the clinical state and the effect of therapy. J Neurol Sci 58: 357–370
Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054–1059
Lindstrom JM, Campbell M, Nave B (1978) Specificities of antibodies to acetylcholine receptors-Muscle Nerve 1: 140–145
Lisak RP (1984) Plasma exchange in neurologic diseases. Arch Neurol 41: 654–657
Lisak RP, Abramsky O, Schotland DL (1979) Plasmapheresis in the treatment of myasthenia gravis: Preliminary study in 21 patients. In: Daun PC (ed) Plasmapheresis and the immunobiolog of myasthenia gravis. Houghton Mifflin, Boston, pp 209–215
Lockwood CM, Worlledge S, Nicholas A, Cotton C, Peters DK (1979) Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 300: 524
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folinphenol reagent. J Biol Chem 193: 265–275
Malchesky PS, Asanuma Y, Zawicki I et al. (1980) On-line separation of macromolecules by membrane filtration with eryogelation. Artif Organs 4: 205–206
Mandy WJ, Nisonoff A (1963) Effect of reduction of several disulfide bonds on the properties and recombination of univalent fragments of rabbit antibody. J Biol Chem 238: 206–213
McCombe PA, Pollard JD, McLeod JG (1987) Chronic inflammatory demyelinating polyradiculoneuropathy. Brain 110: 1617–1630
McCune MA, Winkelmann RK, Osmundson PJ, Pineda AA (1983) Plasma exchange: a controlled study of the effect in patients with Raynaud’s phenomenon and scleroderma. J Clin Apheresis 1: 206–214
Mertens HG, Balzereit F, Leipert H (1969) The treatment of myasthenia gravis with immunosuppressive agents.Eur Neurol 2: 321–329
Messerschmidt GL, Henry DH, Snyder HW jr et al. (1988) Protein A immunoadsorption in the treatment of malignant disease. J Clin Oncol 6: 201–212
Meyer B-U, Benecke R, Göhmann M, Zipper S, Conrad B (1987) Möglichkeiten und Grenzen der Bestimmung zentraler motorischer Leitungszeiten beim Menschen. Z EEG EMG 18: 165–172
Mittag T, Kornfeld P, Tormay A, Woo C (1976) Detection of anti-acetylcholine receptor factors in serum and thymus from patients with myasthenia gravis. N Engl J Med 294: 691–694
Murabayashi S, Omokawa S, Takaoka T, Malchesky PS, Nose Y (1987) Biocompatibility in membrane plasmapheresis: the necessity of global understanding. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI. IS AO Press, Cleveland, pp 27–43
Newsom-Davis J (1979) Plasma exchange in myasthenia gravis. Plasma Ther 1: 17–31
Nikolay J, Braun J, Druschky KF, Greiling HW, Gessler U (1987) Klinische Erfahrung mit der Immunadsorption bei Myasthenia gravis und Polyradikuloneuritis. Nieren Hochdruckkrankh 11: 455–460
Nisonoff A, Wissler FC, Lipman LN, Woernley DL (1960) Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch Biochem Biophys 89: 230–244
Oh SJ (1978) Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol 35: 509–516
Oosterhuis HJGH (1984) Myasthenia gravis. Churchill Livingstone, Edinburgh
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Patrick J, Lindstrom J (1973) Autoimmune response to acetylcholine receptor. Science 180: 871–872
Patten E (1986) Therapeutic plasmapheresis and plasma exchange CRC Crit Rev Clin Lab Sei 23: 147–175
Peterson EA (1970) Cellulosic ion exchangers. In: Work TS, Work E (eds) Laboratory techniques in biochemistry and molecular biology, Vol 2, Part II. North Holland, Amsterdam
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Pineda AA (1985) Apheresis controlled trials: the need for sham procedures-Plasma Ther Transfus Technol 6: 777–780
Pollard JD, McLeod JG, Gatenby P, Kronenberg H (1983) Prediction of response to plasma exchange in chronic relapsing polyneuropathy. J Neurol Sei 58: 269–287
Pollard JD (1987) A critical review of therapies in acute and chronic inflammatory emyelinating polyneuropathies-Muscle Nerve 10: 214–221
Prineas JW, McLeod JG (1976) Chronic relapsing polyneuritis. J Neurol Sei 27: 427–458
Rao VS, Grodzicki RL, Mitchell MS (1979) Specific in vivo inhibition of macrophage receptors for cytophilic antibody by soluble immune complexes. Cancer Res 39: 174–182
Ratnam M, Le Nguyen D, Rivier J, Sargent P, Lindstrom J (1986) Transmembrane topography of the nicotinic acetylcholine receptor: immunochemical tests contradict theoretical predictions based on hydrophobicity profiles. Biochemistry 25: 2633–2643
Reis G von, Liljestrand A, Matell G (1966) Treatment of severe myasthenia gravis with large doses of ACTH. Ann NY Acad Sei 135: 409–416
Rifle G, Tanter Y, Mousson C, Cabanne JF, Chalopin JM (1986) Hazards of plasma exchange: experience of a single center. First International Congress World Apheresis Association. Abstracts, p 50
Roberts WH, Domen RE, Wanger GP, Kennedy MS (1983) Acute copper deficiency in patients undergoing plasma exchange. In: Nose Y, Malchesky PS, Smith JW, Krakauer RS (eds) Plasmapheresis. Raven Press, New York, pp 395–398
Rodnitzky RL, Goeken JA (1982) Complications of plasma exchange in neurological patients. Arch Neurol 39: 350–354
Rosengren J, Pahlman S, Glad M (1975) Hydrophobic Interaction Chromatography on non-charged Sepharose derivatives. Biochim Biophys Acta 412: 51–61
Roitt I, Brostoff J, Male D (1985) Immunology. Gower, London
Saida T, Saida K, Silberberg DH, Brown MJ (1982) In vivo demyelinating activity of sera from patients with Guillain-Barre syndrome. Ann Neurol 11: 69–75
Salinas, FA, Hanna MG jr (eds) Immune complexes and human cancer. In: Contemporary topics in immunobiology, Vol 15. Plenum Press, New York
Samtleben W, Hillebrand G, Krumme D, Gurland HJ (1980) Membrane plasma separation: clinical experience with more than 120 plasma exchanges. In: Sieberth HG (ed) Plasma exchange. Schattauer, Stuttgart, pp 175–178
Sanaka T, Kubo K, Suzuki T et al. (1983) Complications associated with plasma exchange. In: Oda T (ed) Therapeutic plasmapheresis, Vol II Schattauer, Stuttgart, pp 585–589
Sanders ME, Koski CL, Robbins D (1986) Activated terminal complement in cerebrospinal fluid in Guillain-Barrd syndrome and multiple sclerosis. J Immunol 136: 4456–4459
Sato T, Nishimiya J, Arai K, Anno M, Yamawaki M, Kuroda T, Inagaki K (1984) Selective removal of anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis in vitro with a new immunosorbent. In: Oda T (ed) Therapeutic Plasmapheresis, Vol III. Schattauer, Stuttgart, pp 565–568
Scheidegger JJ (1955) Une micro-méthode de l’immuno-électrophorése. Int Arch Allergy 7: 103–110
Schmidt RE, Deicher H (1983) Indikationen zur Anwendung intravenöser Immunglobuline. Dtsch Med Wochenschr 108: 227–231
Schmitt E, Behm E, Buddenhagen F et al. (1988) Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis - First results of a double blind controlled trial. In: Rock G (ed) Apheresis. Alan R. Liss, New York
Schröder JO, Euler HH (1988) Antibody rebound secondary to antibody depletion: experimental evidence and clinical consequences. In: Rock G (ed), Apheresis Alan R. Liss, New York, im Druck
Schumacher CH, Roth P (1912) Thymektomie bei einem Fall von Morbus Basedowi mit Myasthenie. Mitteilung Grenzgeb Med Chir 25: 746–765
Schwab PJ, Fahey JL (1960) Treatment of Waldenstrom’s macroglobulinemia by plasmapheresis. N Engl J Med 263: 574–579
Seki K, Sato T, Komiya T, Ishigaki Y, Kagamihara Y, Tsuda H (1987) Immunodasorption of acetylcholine-receptor antibodies in myasthenia gravis. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic Plasmapheresis, Vol VI. ISAO Press, Cleveland, pp 367–370
Sela M, Mozes E (1966) Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Biochemistry 55: 445–452
Sela M, Mozes E, Shearer GM, Karniely Y (1970) Cellular aspects of the inverse relationship between the net charge of immunogens and of antibodies elicited. Proc Natl Acad Sei 67: 1288–1293
Shibuya N, Shirabe S, Nagasato K, Kanazawa H, Kihara M (1985) Immunoadsorbent plasma perfusion therapy in patients with neuro-immunological disorders. In: Oda T (ed) Therapeutic plasmapheresis, Vol IV. Schattauer, Stuttgart, pp 165–169
Shibuya N, Nagasato K, Shibayama K, Kanazawa H (1987) Immunoadsorption therapy in neurologic diseases: Myasthenia gravis, multiple sclerosis, and Guillain-Barré syndrome. In: Oda T, Shiokawa Y, Inoue N (eds) Therapeutic plasmapheresis, Vol VI ISAO Press, Cleveland, pp 122–128
Sieberth HJ, Glöckner WM, Kierdorf H (1980) Cascade filtration for separating plasma proteins of different molecular weights. Proc EDTA 17: 347–352
Simpson JA (1960) Myasthenia gravis: a new hypothesis. Scott Med J 5: 419–436
Skoog WA, Adams WS (1959) Plasmapheresis in a case of Waldenstrom’s macroglobulinaemia. Clin Res 7: 96–99
Smolens J, Stokes J, Vogt AB (1957) Human plasmapheresis and its effect on autoantibodies. J Immunol 79: 434–439
Sprenger KBG, Kratz W, Huber K, Franz HE (1983) On the quantification of plasma exchange: biological and economical considerations. In: Klinkmann H, Ahrenholz P, Biester FD, JM Courtney, Falkenhagen D, Gaylor JD (eds) Proc. Intern. Symp. on Kinetic Modelling in Artificial Organs. ISAO Press, Rostock, pp 214–218
Sprenger KBG, Rasche H, Franz HE (1984) Membrane plasma separation: Complications and monitoring. Artif Organs 8: 360–363
Sprenger KBG (1985) Plasmapherese. Habilitationsschrift, Düsseldorf
Sprenger KBG (1987) Plasmaaustauschtherapie. Antrittsvorlesung, Düsseldorf
Sterz R, Hohlfeld R, Rajki K, Kaul M, Heininger K, Peper K, Toyka KV (1986) Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab’)2 hybrid molecules. Muscle Nerve 9: 306–312
Steward MW, Steensgard J (1983) Antibody affinity: thermodynamic aspects and biological significance. CRC Press, Boca Raton
Stockinger B, Lemmel E-M (1978) Fc receptor dependency of antibody mediated feedback regulation: on the mechanism of inhibition Cell. Immunol 40: 395–403
Stöhr M, Bluthardt M (1984) Atlas der klinischen Elektromyographie und Neurographie.Kohlhammer, Stuttgart
Chenoweth DE, Cheung AK (1983) Anaphylatoxin formation during haemodialysis: effects of different dialyser membranes. Kidney Int 24: 764 – 769
Sturgill BC, Worzniak MJ (1970) Stimulation of proliferation of 19S antibody-forming cells in the spleens of immunized guinea-pigs after exchange transfusion. Nature 228: 1304–1305
Sugiyama H, Benda P, Meunier J, Changeux JP (1973) Immunological characterisation of the cholinergic receptor protein from Electrophorus electricus. FEBS Lett 35: 124–128
Sutton DMC, Cardella CJ, Uldall PR, Deveber GA (1981) Complications of intensive plasma exchange. Plasma Ther 2: 19–23
Sutton DMC (1986) Complications of therapeutic plasma exchange ( TPE) - the Canadian experience. First International Congress World Apheresis Association (Abstracts) p 49
Szpirt W, Somnier F, Gammeltoft S (1987) Removal of anti-acetylcholine receptor antibodies by immunoadsorption to protein A column. In: Bambauer R, Malchesky PS, Falkenhagen D (eds) Therapeutic Plasma Exchange and Selective Plasma Separation. Schattauer, Stuttgart, pp 385–391
Terman DS, Durante D, Buffaloe G, Mcintosh R (1977) Attenuation of canine nephrotoxic glomerulonephritis with an extracorporeal immunoadsorbent. Scand J Immunol 6: 195–202
Terman DS (1983) Immunoadsorbents in autoimmune and neoplastic diseases. Plasma Ther Transfus Technol 4: 415–433
Thomas PK, Lascelles RG, Hallpike JF, Hewer RL (1969) Recurrent and chronic relapsing Guillain-Barre polyneuritis. Brain 92: 589–606
Toyka KV, Drachman DB, Pestronk A, Kao I (1975) Myasthenia gravis: Passive transfer from man to mouse. Science 190: 397–399
Toyka KV, Becker T, Fateh-Moghadam A et al. (1979) Die Bedeutung der Bestimmung von Antikörpern gegen Acetylcholinrezeptoren in der Diagnostik der Myasthenia gravis. Klin Wochenschr 57: 937–942
Toyka KV, Löwenadler B, Heininger K, Besinger UA, Birnberger KL, Fateh-Moghadam A, Heilbronn E (1980) Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. J Neurol Neurosurg Psychiatry 43: 836–840
Toyka KV, Besinger UA, Heininger K et al. (1981) Myasthenia gravis: The pathogenic role of antibodies to acetyl-choline recptor and the effect of antibody depletion. In: Borberg H, Reuther P (eds) Plasma exchange therapy. Thieme, Stuttgart, pp 172–179
Toyka KV, Augspach R, Wiethölter H et al. (1982) Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor. Muscle Nerve 5: 479–484
Toyka KV (1984) Neurologische Indikation zur Plasmapherese. Aktuel Neurol 11: 114–117
Toyka KV, Heininger K (1986) Acetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis. Dtsch med Wochenschr 111: 1435–1439
Toyka KV, Heininger K (1987) Humoral factors in peripheral nerve disease. Muscle Nerve 10: 222–232
Toyka KV (1987) Klinische Neuroimmunologie. VCH Verlagsgesellschaft, Weinheim
Tullis JL, Trich RJ, Bavdanza P (1971) Plateletpheresis in a disposable system. Transfusion 11: 368–377
Tsuruta Y, Maeda K, Shinzato T et al. (1983) Clinical application of improved 1–02 immunosorbent column. In: Nos6 Y, Malchesky PS, Smith JW (eds), Plasmapheresis ISAO Press, Cleveland, pp 149–154
Tyka WM (1984) Möglichkeiten und Grenzen der Membranplasmaseparation. Dissertation, Dusseldorf Tzartos S, Seybold M, Lindstrom J (1982) Specificity of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sei USA 79: 188–192
Tzartos S, Langeberg L, Hochschwender S, Lindstrom J (1983) Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett 158: 116–118
Underdo wn BJ, Good friend L (1970) Correlation of charge properties of human reaginic antibodies with charge of the corresponding allergens. J Immunol 104: 530–533
Vermeulen M, van der Meche FGA, Speelman JD, Weber A, Busch HFM (1985) Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sei 70: 317–326
Viets HR, Schwab RS (1960) Thymectomy for Myasthenia Gravis. Thomas, Springfield, 111.
Vincent A (1980) Immunology of acetylcholine receptors in relation to myasthenia gravis. Physiol Rev 60: 756–824
Yamazaki Z, Fujimoto Y, Sanjo K et al. (1978) New artificial liver support system (plasma perfusion detoxification) for hepatic coma. Artif Organs 2 (S): 273–276
Yamazaki Z, Fujimori Y, Takahama T et al. (1982) Efficiency and biocompatibility of a new immunosorbent. Trans Am Soc Artif Intern Organs 28: 318–323
Yamazaki Z, Fujimori Y, Iizoka I et al. Immunoadsorbent plasma perfusion in patients with rheumatoid arthritis or systemic lupus erythematosus In: Atsumi K, Maekawa M, Ota K (eds) Progress in artificial organs. ISAO Press, Cleveland, pp 708–712 (1983)
Yang B-H, Sundaram PV, Maelicke A (1981) Affinity chromatography and immunosorption with acetylcholine receptor attached to nylon tubes. Biochem J 199: 317–322
Waldmann TA, Strober W (1969) Metabolism of immunoglobulins. Progr Allergy 13: 1–110
Walker GL (1979) Progressive polyradiculoneuropathy: treatment with azathioprine. Aust NZ J Med 9: 184–187
Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S (1980) Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 244: 2423–2426
Wood GJ, Hall GM (1978) Plasmapheresis and plasma cholesterase. Brit J Anaesth 50: 945–949
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heininger, K. (1993). Literatur. In: In-vitro- und in-vivo-Untersuchungen zur selektiven Immunadsorptionsbehandlung neurologischer Erkrankungen. Schriftenreihe Neurologie, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77092-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-77092-0_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77093-7
Online ISBN: 978-3-642-77092-0
eBook Packages: Springer Book Archive